PubRank

Keith D Lindor

Author PubWeight™ 188.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 15.74
2 Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 4.84
3 The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005 4.65
4 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003 3.22
5 Nonalcoholic fatty liver disease. CMAJ 2005 2.56
6 Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010 2.55
7 Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006 2.48
8 High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011 2.38
9 Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002 2.32
10 Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005 2.15
11 Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004 2.11
12 Nonalcoholic fatty liver disease. Ann Epidemiol 2007 2.09
13 Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004 2.09
14 Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med 2011 2.03
15 Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011 2.01
16 The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004 1.92
17 Primary biliary cirrhosis. Lancet 2003 1.90
18 Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009 1.90
19 Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002 1.69
20 Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2007 1.69
21 Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003 1.68
22 Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009 1.68
23 Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011 1.68
24 Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004 1.65
25 The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005 1.63
26 HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007 1.60
27 Primary sclerosing cholangitis. Lancet 2013 1.59
28 Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002 1.58
29 Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013 1.58
30 A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004 1.56
31 Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005 1.48
32 Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003 1.47
33 Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007 1.46
34 Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008 1.45
35 Research productivity of graduates from 3 physician-scientist training programs. Am J Med 2008 1.44
36 The value of observational research in liver diseases. Hepatology 2011 1.43
37 Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol 2008 1.41
38 Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007 1.39
39 Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004 1.33
40 Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004 1.24
41 Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res 2011 1.23
42 Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002 1.20
43 Primary sclerosing cholangitis. Can J Gastroenterol 2008 1.17
44 Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2010 1.15
45 The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012 1.15
46 Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol 2002 1.14
47 Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2006 1.13
48 Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011 1.12
49 Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003 1.10
50 Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005 1.10
51 Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis 2008 1.09
52 Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol 2010 1.08
53 Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003 1.07
54 Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004 1.06
55 The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol 2005 1.05
56 Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2010 1.05
57 Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005 1.05
58 Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011 1.02
59 Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006 1.02
60 Evaluating sex and gender competencies in the medical curriculum: a case study. Gend Med 2012 1.00
61 When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003 1.00
62 Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012 0.99
63 Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2002 0.99
64 Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007 0.99
65 Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009 0.99
66 Living donor liver transplantation using a right lobe graft in an adult with situs inversus. Liver Transpl 2005 0.97
67 Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013 0.97
68 Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 2013 0.97
69 In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002 0.96
70 Putting the needs of the patient first: Mayo Clinic's core value, institutional culture, and professionalism covenant. Acad Med 2007 0.95
71 Primary sclerosing cholangitis. Inflamm Bowel Dis 2005 0.94
72 Drug-induced cholestasis. Clin Liver Dis 2003 0.94
73 Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2011 0.93
74 Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol 2004 0.93
75 Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006 0.93
76 Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2008 0.93
77 Primary sclerosing cholangitis. Clin Liver Dis 2004 0.92
78 Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014 0.92
79 NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013 0.91
80 American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010 0.91
81 A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Dig Liver Dis 2010 0.90
82 Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol 2011 0.89
83 Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep 2010 0.89
84 Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008 0.88
85 Antibiotics for the treatment of primary sclerosing cholangitis. Am J Ther 2011 0.88
86 Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opin Pharmacother 2010 0.87
87 Current pharmacotherapy for cholestatic liver disease. Expert Opin Pharmacother 2012 0.87
88 Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol 2012 0.87
89 Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2010 0.87
90 Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management. Clin Liver Dis 2012 0.87
91 A model for integration of formal knowledge and clinical experience: the advanced doctoring course at Mayo Medical School. Acad Med 2011 0.86
92 Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol Clin North Am 2008 0.86
93 Autoimmune hepatitis: a review. J Gastroenterol 2012 0.86
94 Value of determining carbohydrate-deficient transferrin isoforms in the diagnosis of alcoholic liver disease. Mayo Clin Proc 2003 0.86
95 Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013 0.85
96 Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis. Gastroenterol Hepatol (N Y) 2010 0.85
97 Current management of primary sclerosing cholangitis in pediatric patients. Paediatr Drugs 2011 0.85
98 Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009 0.85
99 Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol 2012 0.85
100 Commentary: improving medical education during financially challenging times. Acad Med 2010 0.85
101 Mortality attributable to cholestatic liver disease in the United States. Hepatology 2008 0.85
102 Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003 0.84
103 Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases. Expert Rev Gastroenterol Hepatol 2007 0.84
104 Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2011 0.84
105 Cholangiocarcinoma: expanding the spectrum of risk factors. J Gastrointest Cancer 2009 0.83
106 Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005 0.83
107 Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003 0.83
108 Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003 0.83
109 38-year-old woman with abnormal liver enzymes and hyperlipidemia. Mayo Clin Proc 2009 0.83
110 Primary biliary cirrhosis in adults. Expert Rev Gastroenterol Hepatol 2014 0.82
111 Risk of lymphoma in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007 0.82
112 Pregnancy in a patient with primary sclerosing cholangitis. J Clin Gastroenterol 2002 0.81
113 Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002 0.81
114 Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005 0.81
115 Recurrence of primary sclerosing cholangitis: what do we learn from several transplant centers? Liver Transpl 2008 0.80
116 Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 2014 0.80
117 Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 2007 0.80
118 Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011 0.80
119 Clinical management of autoimmune biliary diseases. J Autoimmun 2013 0.80
120 A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010 0.80
121 The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology 2010 0.80
122 The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci 2012 0.79
123 Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2008 0.79
124 Hepatic fibrosis and the renin-angiotensin system. Am J Ther 2011 0.79
125 Serum lipids in primary sclerosing cholangitis. Dig Liver Dis 2011 0.79
126 A novel incentive system for faculty in an academic medical center. Ann Intern Med 2002 0.79
127 Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol 2002 0.79
128 Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig Dis Sci 2006 0.78
129 Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007 0.78
130 A major step towards effective treatment evaluation in primary biliary cirrhosis. J Hepatol 2011 0.78
131 Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int 2007 0.77
132 Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Expert Opin Drug Saf 2015 0.77
133 Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 2003 0.77
134 Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy? Am J Gastroenterol 2010 0.77
135 Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014 0.77
136 Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther 2013 0.77
137 Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003 0.77
138 Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opin Investig Drugs 2005 0.76
139 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 2008 0.76
140 Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol 2014 0.76
141 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci 2009 0.76
142 Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol 2010 0.76
143 Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther 2014 0.76
144 Emerging drugs for the treatment of Primary Biliary Cholangitis. Expert Opin Emerg Drugs 2016 0.76
145 A patient with primary biliary cirrhosis and elevated LDL cholesterol. Clin Chem 2009 0.76
146 Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer 2009 0.76
147 Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thought. Indian J Gastroenterol 2004 0.75
148 Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. J Clin Gastroenterol 2016 0.75
149 Primary sclerosing cholangitis--approach to diagnosis. MedGenMed 2007 0.75
150 Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis? Transl Res 2009 0.75
151 Current concepts in the pathogenesis of primary biliary cirrhosis. Ann Hepatol 2005 0.75
152 A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. Am J Ther 2016 0.75
153 Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol 2004 0.75
154 Primary sclerosing cholangitis: providing a safe and effective treatment. Expert Rev Gastroenterol Hepatol 2012 0.75
155 Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin Liver Dis 2004 0.75
156 Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. Clin Gastroenterol Hepatol 2007 0.75
157 Dr. H. Butt tribute. Hepatology 2008 0.75
158 A 42-year-old woman with a new diagnosis of sclerosing cholangitis. Clin Gastroenterol Hepatol 2012 0.75
159 Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011 0.75
160 Docetaxel Induced Sclerosing Cholangitis. Dig Dis Sci 2015 0.75
161 Sclerosing cholangitis. Curr Opin Gastroenterol 2002 0.75
162 A new section: image of the month. Hepatology 2009 0.75
163 Diagnostic and therapeutic advances in hepatology: a new feature in the journal. Hepatology 2010 0.75